Oncology has become a growing area of interest for pharmaceutical companies over the years. With a significant increase in R&D and healthcare spending worldwide, companies ranging from large pharmaceutical conglomerates to smaller biotech organizations are frantically attempting to capitalize on lucrative market opportunities. As a result, pipeline activities for the most common cancers - breast, lung, prostate, and colorectal cancer - have been accelerated. Aside from solid tumors, hematological malignancies have seen an increase in clinical activity.
Traditional cancer treatment options such as surgery, radiation therapy, and chemotherapy remain the mainstays...
